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 Triplet excited states exhibit strongly medium-dependent properties, which turns 
them into valuable tools to probe the microenvironments existing in protein binding 
pockets. Monitoring of the triplet excited state behavior of drugs within transport proteins 
(serum albumins and 1-acid glycoproteins) by laser flash photolysis constitutes a 
valuable source of information on interaction strength, conformational restrictions and 
protection from attack by oxygen or other external reagents. With proteins, formation of 
encapsulated triplet excited states is favored over other possible processes leading to ionic 
species. Remarkably, under aerobic conditions, the triplet lifetimes of drug@protein 
complexes are dramatically longer than in bulk solution. This offers a broad dynamic 
range for identification of distinct triplet populations or for chiral discrimination. In this 
review, specific applications of the laser flash photolysis technique are described, 
including determination of drug distribution among the bulk solution and the protein 
binding sites, competition of two types of proteins to bind a drug, occurrence of drug-
drug interactions within protein binding sites, and enzymatic-like activity of the proteins. 
Finally, protein encapsulation can also modify the photoreactivity of the guest. This is 
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1. Introduction  
 In the laser flash photolysis (LFP) technique, a short pulse of light (nano or 
femtoseconds) from a laser is used to interact with a sample that is located in the optical 
path of a spectrometer; the result of this interaction can be either a transient absorption or 
emission process. The signal detected following laser excitation of a substrate may be due 
to a variety of transient species such as i) triplet excited states (TES) formed after 
electronic excitation followed by intersystem crossing, ii) radicals obtained by homolytic 
bond cleavage, iii) radical ions resulting from electron transfer, iv) isomers obtained after 
rearrangement, etc.1 (Scheme 1). 
  h 1A A*   
  ISC1 3A*   A*                                        (i) 
  1 3A* or A*   a  + b                                    (ii) 
  1 3 +. -.A* or A*    A  or A                   (iii) 
  1 3A* or A*  A'                                (iv) 
Scheme 1. Transient species detectable by LFP. 
 Transient absorption spectroscopy (TAS) has been much less exploited than 
fluorescence emission to investigate bio(chemical) issues, although it constitutes a 
powerful tool for this purpose. A schematic representation of an LFP equipment are 





Figure 1. Schematic representation of an LFP setup. 
 
 The behavior of TES of ligands after protein encapsulation can be easily monitored by 
employing LFP. The properties of TES (especially the triplet lifetimes, T) are very 
sensitive to the microenvironment experienced within the protein binding sites, and thus 
they can be successfully employed to investigate the issue of drug binding (see cartoon 
in Figure 2), providing information on interaction strength, conformational restrictions, 





















































 Drugs suitable for monitoring TES within proteins should possess a chromophore able 
to absorb the laser irradiation, with a non-negligible intersystem crossing quantum yield 
and a triplet lifetime in the nanosecond-microsecond time scale. For this purpose, drugs 
containing chromophores such as biphenyl (flurbiprofen), naphthalene (naproxen, 
cinacalcet, propranolol, nabumetone) or anthracene (anthracenealkanoic acids) are 
specially appropriate. As additional requirements, the protein should not absorb or it 
should not produce any signal in the wavelength region where the drug intermediates do, 
and the product of the molar absorption coefficient of the excited state by the intersystem 
crossing quantum yield has to remain constant in the absence and presence of protein. 
 Most of the work on the use of TES for obtaining relevant bio(chemical) information 
has been done with transport proteins (TP), such as human and bovine serum albumin 
(HSA, BSA) or 1-acid glycoproteins (HAAG, BAAG). These proteins are very abundant 
in plasma and are responsible for a variety of relevant processes, although one of their 
most important physiological roles is to carry different agents (i.e. drugs or metabolites) 
in the bloodstream for their selective delivery to specific targets. 2,3,4 In addition, the role 
of plasma protein binding has been recognized as an important factor in drug disposition 
and efficacy.5 In this context, drug binding to TP is a key process, which is involved in 
phenomena such as modulation of drugs solubility in plasma, toxicity, in vivo half-life, 
etc.6 Concerning serum albumins, they are major carriers of small organic molecules, 
which bind primarily to two high-affinity sites (called site I or warfarin binding site and 
site II or indole–benzodiazepine binding site), with typical association constants in the 
range of 104–106 M-1.7 As regards 1-acid glycoproteins, their concentration in serum is 
much lower than that of albumins. For HAAG, up to seven binding sites have been 
described, although most small organic molecules bind exclusively to one of them.8,9 This 
high-affinity site is large and flexible, and the areas for basic, acid, and neutral drugs 
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overlap. For BAAG, a substantial overlap of a basic drug and a steroid hormone binding 
sites has been described.  
 Binding of drugs to TP has been studied for years with different methodologies, in 
order to understand their functions and to disclose the structural basis for designing new 
therapeutic agents. The techniques include equilibrium dialysis, high performance liquid 
chromatography, ultrafiltration, spectrophotometry, calorimetry, circular dichroism, 
capillary electrophoresis, nuclear magnetic resonance, etc.10 Although in general these 
techniques are useful and widely employed, their main disadvantages can be related to 
sensitivity, interferences, diffusion problems or lack of reproducibility arising from a 
complicated workup. Some of these problems can be circumvented by means of TAS, 
which can be envisaged as a complementary tool. The LFP-based approach is fast and 
simple, as it may require just one measurement per sample to provide accurate results. It 
is highly sensitive and is appropriate for analysis of minute (mg) amounts of sample. As 
further advantages, it avoids work-up, substrate derivatization and chromatographic 
separation.11 
 In this review, some representative applications of the LFP technique on drug/transport 
protein systems are detailed. They include issues such as the determination of drug 
distribution among the bulk solution and the protein binding sites, competition of two 
proteins to bind a ligand, drug-drug interactions within protein binding sites, enzymatic-
like activity of serum albumin or determination of enantiomeric compositions. The 
chemical structures of the drugs or ligands whose behavior is described in this review are 
















Chart 1. Chemical structures of the drugs and ligands described in this work.  
 
2. Drug binding within the protein binding sites 
 When drugs are bound to proteins, their time of action is prolonged by retarding 
metabolization. Only unbound drugs are pharmacologically active. The extent of binding 
depends on total drug concentrations and on protein affinity. The process is usually 
reversible, and equilibrium is established between bound and free drug. A high protein 
binding affinity results in improved solubility and increased half-life. Conversely, a low 
value of this parameter is associated with limited ability to perfuse tissues and to reach 
the site of action.12,13,14 
 In this context, LFP-based methodologies have been developed to assess protein 
occupancy in the presence of one or two different transport proteins and to reveal drug-






















R' = H: 9-Anthraceneacetic  acid (ANA) 
R' = CH3: 2-(9-Anthracenyl)-propionic acid (ANP)
Nabumetone (NAB)
Naproxen (NPX) Propranolol (PPN)
R = H: Flurbiprofen (FBP)




2.1. Assesment of protein occupancy 
 A well-documented example on the use of TAS to establish protein occupancy degree 
is the case of the non-steroidal anti-inflammatory drug flurbiprofen15 (FBP, Chart 1), 
which belongs to the arylpropionic acid family and contains a chiral center. The transient 
spectrum of (S)-FBP obtained after laser excitation at 266 nm (PBS, air), displays a 







Figure 3. Laser flash photolysis (lexc = 266 nm) of (S)-FBP (2.5 × 10-5, PBS, air). A: Transient 
spectrum obtained 0.5 ms after the laser pulse. B: Kinetic decays monitored at l= 360 nm after 
addition of different amounts of HSA. 
 
 The kinetic decay trace (Figure 3B) follows a first order exponential law with a lifetime 
(F) of 1.5 ms (Eq. 1).  
F(-t/τ )
0 FΔA=ΔA +A ×e    (Eq. 1) 
 After addition of HSA (0.7:1 drug/protein molar ratio), 3FBP* is still the only transient 
species detected, but the kinetic trace at lmax = 360 nm is now longer lived (Figure 3B); 
two monoexponential terms are now necessary for fitting (Eq. 2), with lifetimes of 11.2 
and 35.9 ms (minor and major components, respectively).  
I II(-t/τ ) (-t/τ )
0 I IIΔA=ΔA +A ×e +A ×e    (Eq. 2) 
 They are ascribed to FBP within site I (I) and site II (II) of HSA, respectively, based 
on the known higher affinity of FBP for site II.17 To obtain independent evidence 
 



































supporting this assignment, LFP experiments have been performed in the presence of (S)-
ibuprofen ((S)-IBP) as site II-probe.18 Addition of (S)-IBP to the (S)-FBP/HSA mixtures 
results in a decreased contribution of the longest lifetime component, concomitant to an 







Figure 4. Displacement experiments in the presence of IBP. 
 
 For solutions prepared at different drug/protein molar ratios (from 1.4:1 to 0.3:1), 
fitting of the decay traces contains three monoexponential terms (Eq. 3), supporting 
distribution of the drug among the two protein binding sites and the bulk solution.  
F I II(-t/τ ) (-t/τ ) (-t/τ )
0 F I IIΔA=ΔA +A ×e +A ×e +A ×e    (Eq. 3) 
 In this equation, subscripts F, I  and II indicate contribution of free, site I-bound and 
site II-bound drug, respectively. After dividing each preexponential coefficient AF, AI or 
AII by the sum of the three Ai values (AF + AI + AII), the percentage of free and bound 
drug at different amounts of HSA is determined (Figure 5). It can be shown that site II is 
selectively populated at low (S)-FBP/HSA molar ratios, whereas at high ratios most of 























Figure 5. (S)-FBP distribution in HSA at different drug/protein molar ratios. 
 
 The work has been extended to (R)-FBP in HSA and to both enantiomers in BSA. The 
most significant differences between both albumins are related to the dynamic ranges 
found for the triplet lifetimes and to the relative occupancy of the two binding sites.  
 In general, the lengthening of the T values when encapsulated within proteins 
indicates a lower reactivity of the TES, which is mainly attributed to protection of 3FBP* 
from attack by oxygen, which is supported by the high value of the rate constant for triplet 
quenching by oxygen for free (S)-FBP in PBS (1 × 1010 M-1 s-1), compared to the values 
in site I or site II, that are one and two orders of magnitude lower, respectively. In 
addition, triplet decay by nonradiative processes is also retarded, due to a limitation of 
the degrees of freedom inside the TP cavities. The methodology has also been 
successfully applied to establish the protein binding behavior of FBP methyl esther (a 
prodrug).19 
 
2.2. Determination of drug distribution in a binary protein system 
 A new methodology aimed at a rapid and reliable assessment of drug distribution 
between two proteins present simultaneously in a biological medium has been developed, 






























Site II bound (S)-FBP










Occupancy rate in (S)-FBP/HSA systems
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obtained from the decay curves in the presence of serum albumin/glycoprotein binary 
systems.20 A representative example is provided by the study of three naphthalene-
derived drugs,21 with a (known) different affinity for the two types of proteins: cinacalcet 
(CIN, a calcimimetic),22 naproxen (NPX, a NSAID)23 and propranolol (PPN, an 
antihypertensive).24 Their chemical structures can be found in Chart 1. 
 Prior to analysis of the binary systems, the binding behavior in the presence of isolated 
proteins is established. Starting with CIN, the excited states of the (R)-enantiomer have 
been characterized in order to obtain relevant information about its complexation with 
HSA.25 Upon LFP of (R)-CIN@HSA (lexc = 308 nm, air), naphthalene-like TES are 
generated, with absorption maxima at 420 nm. The corresponding decays are 
satisfactorily fitted using a function containing two monoexponential terms, 
corresponding to a short-lived and a long-lived component (8 ms and 37 ms, respectively), 
different from the value found in pure PBS (1.9 ms), indicating that the drug is 
incorporated into two different binding sites of HSA. Interestingly (R)-CIN exhibits also 
a significant affinity towards glycoproteins, although the drug is located within the only 
existing binding site (Eq. 4, with subscripts F and B indicating contribution of free and 
HAAG bound drug, respectively), with a triplet lifetime of 15 ms in HAAG. 
F B(-t/τ ) (-t/τ )
0 F BΔA=ΔA +A ×e +A ×e    (Eq. 4) 
 Likewise, upon LFP of (S)-PPN at lexc = 308 nm, the transient spectrum shows 
contributions due to 3PPN* and the radical cation (PPN+.). From the decay traces 
monitored at 420 nm under aerobic conditions, their lifetimes have been determined as 
1.9 and 13.5 ms, respectively. The spectra in the presence and in the absence of albumins 
are almost coincident, which is in good agreement with negligible PPN binding to these 
proteins. However, in the presence of glycoproteins, the kinetics are markedly different: 
the decay traces lengthen and require a function containing three monoexponential terms 
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(Eq. 5, with superscripts T and RC indicating contribution of triplet and radical cation 
species, respectively) for a satisfactory fitting, corresponding to two free species (3PPN* 
and PPN+.) plus the longer lived protein-bound triplet.  
(-t/τ ) (-t/τ ) (-t/τ )T T RC
0 F B FΔA=ΔA +A ×e +A ×e +A ×e
T T RC
F B F    (Eq. 5) 
Regression analysis of the decay curves for different PPN/glycoprotein mixtures leads to 
the preexponential factors and hence to the amount of free and bound PPN. Thus, at 1:1 
drug/protein molar ratio a 45% of (R)-PPN is bound to HAAG.  
 The photobehavior of (S)-NPX in the presence of HSA has been investigated by LFP 
at 308 nm in PBS/air. In the absence of protein, a complex transient spectrum is observed, 
with the main maximum at 440 nm (3NPX*, 1.8 ms) and a weaker band in the range 550-
650 nm (NPX+.). However, in the presence of different amounts of albumin, only 3NPX* 
is observed, with the kinetic traces at 440 decaying at longer timescales. At 1:1 molar 
ratio, a satisfactory fitting is obtained considering two monoexponential terms (Eq. 2), 
whereas at higher drug/protein ratios, three lifetime values are necessary to obtain a good 
fitting of the decay signal (Eq. 3). This is ascribed to the presence of two long-lived 
NPX@HSA species, in addition to free NPX. Fitting of the decay curves for NPX/HSA 
ratios from 1:0.15 to 1:1 allows determining the values of the preexponential coefficients, 
corresponding to free, site-I bound, and site-II-bound drug. By contrast, a different 
behavior is observed in the presence of HAAG, where the binding degree is markedly 
lower. Thus, with equimolar amounts of glycoprotein, two triplet lifetimes are found (Eq. 
4), corresponding to free and bound drug; the binding degree is 19%.  
 Then, NPX, PPN, and CIN have been employed for the assessment of drug 
distribution in binary protein systems. Upon LFP of the three drugs in the presence or 
absence of proteins, the naphthalene triplet excited state at 420-440 nm is always detected, 
although the decay kinetics is structure- and medium-dependent. Experiments performed 
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in HSA/HAAG show that when the two proteins are present simultaneously in the same 
medium, fitting of the decay traces is clearly consistent with a distribution of the drug 
between the different biological compartments and the bulk solution, which correlates 
well with the known protein affinities of each drug.  
 The results demonstrate that albumins are the major carriers for NPX, while PPN binds 
preferentially to glycoproteins. An intermediate situation is found for CIN, which 
presents comparable affinity for both types of proteins. Figure 6 shows the decay kinetics 












Figure 6. A. Laser flash photolysis of (S)-NPX, (S)-PPN and (R)-CIN (lexc = 308 nm or 
266 nm, lmon = 420 nm, PBS, air, A308 or 266 nm = 0.3). Kinetic decays in the absence or 
presence of HSA and/or HAAG. B. Drug distribution obtained after fitting of the decay 
curves at drug/HSA/HAAG 1:0.5:0.5 molar ratio. 
 
2.3. Drug-drug interactions revealed by triplet-triplet energy transfer 
 The feasibility of drug-drug interactions (DDI) within the binding sites of TP has been 
probed by TAS, using drug pairs (CIN/PPN and CIN/NAB) complexed within HAAG or 
BAAG.26 The concept involves detection of triplet-triplet energy transfer (TTET), which 
 













































































requires a close proximity between the donor and acceptor partners and can only occur 
within a common biological compartment.  
 The behavior of CIN/HAAG and PPN/HAAG has been described in the precedent 
section. Concerning nabumetone (4-[6-methoxy-2-naphthy1]-2-butanone, NAB) it acts 
as prodrug, being metabolized by the liver to 6-methoxy-2-naphthylacetic acid, the active 
pharmacological form.27 Binding to HAAG and BAAG has also been investigated after 
LFP at 308 nm under air; protein bound 3NAB* decays with a T value of 16.6 in HAAG 
and 25.8 ms in BAAG.  
 In the absence of glycoproteins, the drug mixtures are not soluble in PBS and give 
rise to turbid suspensions. Complexation of CIN/PPN and CIN/NAB mixtures with 
glycoproteins is easily followed by naked eye, through a complete solubilization that 
leads to clear preparations. When a solution of CIN/PPN/HAAG at 1:1:1 molar ratio is 
submitted to LFP (lexc = 308 nm, air), the decay trace monitored at 450 nm matches with 
that of the CIN/HAAG system, with no contribution from 3PPN* in the kinetic decay. A 
similar situation is observed in the presence of BAAG. Likewise, for the 
CIN/NAB/glycoprotein systems, the decay traces at 450 nm are identical to those of the 
CIN/glycoprotein mixtures, and 3NAB* does not contribute to the kinetic decay (Figure 
7). These results clearly indicate an efficient energy transfer from 3PPN* or 3NAB* to 
CIN and reveal the occurrence of DDI between drugs that share a common protein 
binding site. As the TTET process is completed within the duration of the laser pulse (< 
20 ns), deactivation of the excited triplet states is extremely fast, with a rate constant 
higher than 5 × 107 s-1. Such a high value is not compatible with the expectedly slow 
diffusion inside the protein binding sites and points to formation of pre-associated 
complexes between donor (PPN or NAB) and acceptor (CIN). This is confirmed by 
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Figure 7. Laser flash photolysis of drug1/HAAG and drug1/drug2/HAAG mixtures (lexc 
= 308 nm, lmon = 420 nm, PBS, air, A308 = 0.3). A: CIN/PPN and B: CIN/NAB systems. 
 
3. Reactivity upon protein complexation 
 The use of proteins as supramolecular systems to influence the course of organic 
reactions has attracted increasing interest over the last decades. Specifically, the 
photoreactivity of encapsulated substrates can be modified by providing protection from 
attack by oxygen or other external reagents, by imposing conformational restrictions in 
the binding pockets, or by influencing the stereochemical outcome through the supply of 
a chiral source. Two examples demonstrating the concept are presented below. 
 
3.1 Monitoring the enzyme-like activity of HSA  
The -1-O-acyl glucuronide metabolites are intrinsically reactive molecules (both in vivo 
and in vitro) that can undergo a number of reactions; by far, hydrolysis back to the parent 
aglycon is the predominating process.28 This reaction can be catalyzed by several agents 
(-glucuronidases, esterases, etc.) resulting in a futile cycle, since plasma clearance is the 
result of competition between conjugation of the parent drug, deconjugation of the 
glucuronide, and renal clearance.29 
 


















































 The glucuronidase activity of HSA towards the glucuronides of FBP, (2R)- and (2S)-
FBPG (Chart 1) has been investigated by in situ TAS. 30 It is based on LFP of both 
glucuronides in the presence of HSA, with the FBP-like TES as reporter. Upon LFP of 
(2R)-FBPGluc (lexc = 266 nm, PBS, air) a transient spectrum with maximum at 360 nm 
is observed, corresponding to TES. Under these conditions, its lifetime is 1.8 ms. In the 
presence of different amounts of HSA, LFP of (2R)-FBPG also gives rise to the 
characteristic 360 nm signal. Unlike the behavior in the absence of protein, the decays do 
not follow a first order exponential law, but require biexponential fitting and take place 
at longer timescales. An important contribution of the 1.8 ms component is always found, 
indicating that free (2R)-FBPG is present in the bulk solution within the entire 
concentration range. The other component, much longer lived (T = 25 ms), is attributed 
to (2R)-FBPG triplet inside the protein cavities. From the AF and AB coefficients, the 
percentages of the two (free and bound) species with different lifetimes are obtained. 
 Several observations deserve special comments for their relevant biological 
implications. First, even at low FBPG/HSA molar ratios, a high amount of glucuronide 
remains unbound to the protein. This is in good agreement with its enhanced 
hydrosolubility respect to the parent drug, which facilitates elimination; moreover, no 
stereodifferentiation takes place in the protein-binding process, since the binding degree 
determined from AF and AB is very similar for both metabolites. In addition, it is worth 
mentioning that only a type of microenvironment is provided by the protein for bound 
FBPG, unlike the case of the parent drug FBP, where two different triplet lifetimes are 
found corresponding to different binding sites.  
 After establishing that the methodology is suitable to discriminate between the drug 
and its metabolite, LFP has been applied to investigate in situ the glucuronidase activity 
of HSA at physiological temperature (37 ºC). Since the amount of complexed glucuronide 
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is higher in an excess of albumin, the 1:3.33 ratio is chosen to monitor the reaction. 
Aliquots of the solution are taken at different times and submitted to LFP. Again, a signal 
centered at 360 nm is observed, but now four different T values are needed to obtain an 
accurate fitting of the decay: the two values reported above for (2R)-FBPG at zero time 
(1.8 and 25 ms), plus the two ones ascribed to (R)-FBP within the protein binding sites 
(10.2 and 39.0 ms). This observation clearly indicates that the hydrolysis process is taking 
place. No (R)-FBP is expected to be present free in solution under these conditions, since 
inclusion within the protein is known to be complete even at higher molar ratios. The four 
characteristic triplet lifetimes are now exploited to determine the percentage of 
compounds in each sample after different reaction times. In the fitting (Eq. 6), F
FBPG is 
the triplet lifetime of free (2R)-FBPG, I
FBP and II
FBP are the corresponding values for 
(R)-FBP within site I and site II, and B
FBPG is he value for (2R)-FBPG bound to the 
protein.  
FBPG FBPG FBP FBP
F B I II(-t/τ ) (-t/τ ) (-t/τ ) (-t/τ )
0 F B I IIΔA=ΔA +A ×e +A ×e +A ×e +A ×e    (Eq. 6) 
Assuming that AI/AII remains constant for FPB, the preexponential factors and 
consequently the percentages of (R)-FBP and (2R)-FBPGluc, can be obtained. The course 
of the reaction, expressed as the percentages of the various species at different times, is 






Figure 8. Percentages of free and bound (2R)-FPBG, as well as (R)-FBP in site I and site II in 





(R)-FBP in site I











 Similar studies conducted at 22 ºC in the presence of protein or at 37 ºC in the absence 
of HSA show a much slower process. 
 
3.2. Enhanced drug photostability of the ligand upon protein encapsulation 
 Photooxidation of 9-anthaceneacetic acid (ANA, Chart 1) has been examined using 
different transport proteins such as HSA, BSA, HAAG and BAAG at 1:1 molar ratio.31 
Irradiation of ANA in aerated PBS solutions yields anthraquinone through TTET from 
3ANA* to molecular oxygen, generating singlet oxygen (1O2). This species reacts with 
the central anthracene ring of ANA leading to an endoperoxide which undergoes 
rearrangement followed by cleavage of the 9-substituent to afford anthraquinone (ANQ), 
as summarized in Scheme 2. 
  h 1ANA ANA*   
  ISC1 3ANA*   ANA*  
  ANA* + O   ANA + O3 3 12 2  
  
2
ANA + O ANA-O  ANQ 1 2  
Scheme 2. Generation and reactivity of singlet oxygen following irradiation of ANA. 
 Within proteins, photooxidation is markedly slower than in bulk solution; the most 
remarkable effect is found for serum albumins, where the reaction rate constant is one 
order of magnitude lower. This important protection provided by protein cavities is 
attributed to a slower diffusion of oxygen inside the protein. In pure PBS, ionic transient 
species such as the radical anion (labs = 350 and 420 nm), the radical cation (labs = 600-
750 nm) and hydrated electron (labs = 700 nm) can be observed (Figure 9A), together 
19 
 








Figure 9. Laser flash photolysis of ANA (lexc = 355 nm, PBS, air, A355 = 0.3). A: PBS 
solution B: In the presence of HSA at 1:1 molar ratio. 
 
 A dramatic stereodifferentiation in the photooxidation process has been found in the 
related 9-anthracenepropanoic acids (S)- and (R)-ANP (Chart 1). For instance, in the 
presence of HSA the reaction rate constant is higher for the (S)-enantiomer, leading to a 
kinetic resolution with enhancement of the less reactive (R)-ANP. A similar behavior is 
observed within glycoproteins (Figure 10). From a mechanistic point of view, 
involvement of singlet oxygen in the photooxidation is confirmed by the remarkable 
acceleration of reaction rates in D2O, in agreement with the longer lifetime of 
1O2 in this 
medium. Overall, the retarded photooxidation within the protein binding sites is in good 
agreement with the lower rate constants obtained for quenching of encapsulated 3ANP* 
by oxygen. Further experiments using selectively excited photosensitizers that are not 
present in the same microenvironments as ANP demonstrate that photooxidation is 
compartmentalized.  
 






























Figure 10. Kinetics of irradiation of ANP in aqueous media/air (lexc > 350 nm) in the presence 
and in the absence of glycoprotein (1:1 drug/protein molar ratio). 
 
4. Conclusions 
 Binding to proteins plays an important role in the pharmacological activity, 
biodistribution and metabolism of drugs. Drug/protein supramolecular assemblies can be 
advantageously investigated by photophysical methods (noteworthy transient absorption 
spectroscopy) when the drugs of interest contain a photoactive chromophore. This is 
particularly useful when such chromophore can be selectively excited at long 
wavelengths, where the aromatic amino acids of the proteins do not absorb. Since triplet 
excited states exhibit strongly medium-dependent properties, they can be used as 
reporters to probe the microenvironments defined by the lipophilic protein binding sites, 
where their formation is strongly favored over generation of ionic species upon laser flash 
photolysis. The resulting 3drug*@protein complexes display photophysical properties 
that can be exploited to gather information on conformational restrictions, interaction 
strength, or protection from attack by oxygen or other agents. Interestingly, the triplet 
lifetimes of protein-complexed drugs are remarkably long (even under aerobic 
conditions), which provides a broad dynamic range for identification of distinct 
populations or for chiral discrimination. The use of proteins as supramolecular vessels 
modifies the photoreactivity of encapsulated substrates by controlling the exchange flow 
of reactants between the bulk solution and the protein binding sites, by imposing 



















conformational restrictions, by making use of the amino acid residues as active centers, 
or by supplying a chiral source. 
 In this review, some examples of the use of TES to obtain relevant information have 
been described. The technique has also been successfully employed for other purposes, 
such as the drug photobinding to proteins in photoallergy,32 determination of 
enantiomeric composition in mixtures of enantiomers33 or inhibition of ligand 
deprotonation after protein encapsulation.34 
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